Care Location | Year | Country | Design | Intervention | Comparator | Number of participants | Uptake (%) | SVR (%) |
---|---|---|---|---|---|---|---|---|
Primary Care | Â | Â | Â | Â | Â | Â | Â | Â |
Bloom | 2017 | Australia | Prospective cohort study of treatment uptake and SVR | Adherence to DAA treatment protocols | Treatment by tertiary care provider | 1044 | 503 (40.6) | 253 (50.2) |
Francheville | 2017 | Canada | Prospective observational study design | Specialist nurse-led care | No comparator group | 242 | 93 (38.4) | 82 (88.2) |
Kattakuzhy | 2017 | USA | Non-randomised open label study | Treatment by primary care providers (PCP) and nurse practitioners (NP) | Standard care - Treatment by secondary care clinic | NP 150 PCP 160 | Â | NP 134 (89.3) PCP139(86.9) |
McCLure | 2017 | Australia | Retrospective data analysis of SVR12 | Nurse-led care and GP remote consultation | Specialist care in Tertiary centre | Nurse-led 70 | 50 (74.3) | 46 (65.7) |
Miller | 2016 | USA | Retrospective observational study | Treatment by primary care providers | No comparator group | 95 | Â | 79 (83) |
Norton | 2017 | USA | Retrospective cohort study of SVR | Treatment in urban primary care centre | SVR 12 in PWIDs and non_PWIDs | 89 | Â | 85(95.5) |
Wade | 2018 | Australia | Randomised controlled trial | Testing, assessment and treatment in primary care | Testing, assessment and treatment in tertiary care | 59 | 31 (52.5) | 14 (23.7) |
Integrated Health Systems (ECHO) | Â | Â | Â | Â | Â | Â | Â | Â |
Abdulameer | 2016 | USA | Retrospective data analysis of SVR 12 | VA-Echo model supporting primary care providers | No comparator group | 588 | Â | 318 (54) |
Beste | 2017 | USA | Retrospective cohort study of treatment uptake and SVR | VA-Echo model supporting primary care providers | Standard care - Treatment by unexposed primary care providers | 6431 | 1303 (21.4) | (58.2) |
Buchanan | 2015 | United Kingdom | Retrospective data analysis | Community-based outreach clinic | Standard care - Treatment by secondary care clinic | 77 | 24 (31.2) | Â |
Georgie | 2016 | USA | Retrospective data analysis of SVR12 | VA-Echo model supporting primary care providers | Treatment by sub-specialist providers | 623 | Â | Genotype 1 (GT1) (99) GT2 (98) GT3 (79) |
Opioid Treatment Centres | Â | Â | Â | Â | Â | Â | Â | Â |
Butner | 2017 | USA | Retrospective data analysis | Opioid treatment programme | No comparator group | 75 | 75.0 | 64 (85.0) |
Morris | 2017 | Australia | Retrospective data analysis of treatment uptake and SVR | Treatment in a community-based harm reduction and treatment facility | No comparator group | 127 | 122 (96) | 102 (80.3) |
Read | 2017 | Australia | Retrospective data analysis of SVR12 | Treatment of PWIDs in primary care setting | No comparator group | 72 | Â | 59 (81.9) |
Pharmacies / Pharmacist Clinics | Â | Â | Â | Â | Â | Â | Â | Â |
David | 2017 | USA | Retrospective data analysis of SVR12 | Pharmacy-managed clinics | Treatment by non-pharmacist providers | 204 | Â | (83.6) |
Radley | 2017 | United Kingdom | Pilot cluster RCT of treatment uptake and SVR | Treatment in community Pharmacy | Treatment by secondary care clinic | 26 | 3 (11.5) | 3 (11.5) |
Telemedicine | Â | Â | Â | Â | Â | Â | Â | Â |
Cooper | 2017 | Canada | Retrospective cohort study of treatment uptake and SVR | Use of telemedicine | Treatment by secondary care clinic | 157 | 35.0 | 18 (11.5) |